FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099822807> ?p ?o ?g. }

• W2099822807 endingPage "36" @default.
• W2099822807 startingPage "33" @default.
• W2099822807 abstract "<b>Purpose:</b> Sorafenib leads to clinical benefit in a subgroup of patients, while all are exposed to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study was to evaluate whether ¹¹C-sorafenib and ¹⁵O-H₂O PET have potential to predict treatment efficacy. <b>Methods:</b> In this prospective exploratory study, 8 patients with advanced solid malignancies and an indication for sorafenib treatment were included. Microdose ¹¹C-sorafenib and perfusion ¹⁵O-H₂O dynamic PET scans were performed before and after two weeks of sorafenib therapy. The main objective was to assess whether tumor ¹¹C-sorafenib uptake predicts sorafenib concentrations during therapy in corresponding tumor biopsies measured with liquid chromatography tandem mass spectrometry (LC-MS/MS). Secondary objectives included the association of ¹¹C-sorafenib PET, perfusion ¹⁵O-H₂O PET and sorafenib concentrations after therapeutic dosing with response. <b>Results:</b>¹¹C-sorafenib PET did not predict sorafenib concentrations in tumor biopsies during therapy. In addition, sorafenib plasma and tumor concentrations, were not associated with clinical outcome in this exploratory study. Higher ¹¹C-sorafenib accumulation in tumors at baseline and day 14 of treatment showed association with poorer prognosis and was correlated with tumor perfusion (rs = 0.671, <i>P</i> = 0.020). Interestingly, a decrease in tumor perfusion measured with ¹⁵O-H₂O PET after only 14 days of therapy showed an association with response, with a decrease in tumor perfusion of 56% ± 23% (mean ± SD) versus 18% ± 32% in patients with stable and progressive disease, respectively. <b>Conclusion:</b> Microdose ¹¹C-sorafenib PET did not predict intratumoral sorafenib concentrations after therapeutic dosing, but the association between a decrease in tumor perfusion and clinical benefit warrants further investigation." @default.
• W2099822807 created "2016-06-24" @default.
• W2099822807 creator A5010130730 @default.
• W2099822807 creator A5016938895 @default.
• W2099822807 creator A5070757819 @default.
• W2099822807 date "1977-01-01" @default.
• W2099822807 modified "2023-09-23" @default.
• W2099822807 title "Zinc in ulcerative colitis: a therapeutic trial and report on plasma levels." @default.
• W2099822807 cites W147241222 @default.
• W2099822807 cites W1964233609 @default.
• W2099822807 cites W1974507297 @default.
• W2099822807 cites W1983100216 @default.
• W2099822807 cites W2012934334 @default.
• W2099822807 cites W2023731024 @default.
• W2099822807 cites W2028125300 @default.
• W2099822807 cites W2034157025 @default.
• W2099822807 cites W2067893300 @default.
• W2099822807 cites W2121089562 @default.
• W2099822807 cites W2158992269 @default.
• W2099822807 cites W2163983137 @default.
• W2099822807 cites W2171789845 @default.
• W2099822807 doi "https://doi.org/10.1136/gut.18.1.33" @default.
• W2099822807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1411260" @default.
• W2099822807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/320111" @default.
• W2099822807 hasPublicationYear "1977" @default.
• W2099822807 type Work @default.
• W2099822807 sameAs 2099822807 @default.
• W2099822807 citedByCount "23" @default.
• W2099822807 countsByYear W20998228072012 @default.
• W2099822807 countsByYear W20998228072013 @default.
• W2099822807 countsByYear W20998228072019 @default.
• W2099822807 countsByYear W20998228072021 @default.
• W2099822807 crossrefType "journal-article" @default.
• W2099822807 hasAuthorship W2099822807A5010130730 @default.
• W2099822807 hasAuthorship W2099822807A5016938895 @default.
• W2099822807 hasAuthorship W2099822807A5070757819 @default.
• W2099822807 hasBestOaLocation W20998228071 @default.
• W2099822807 hasConcept C126322002 @default.
• W2099822807 hasConcept C2777288759 @default.
• W2099822807 hasConcept C2778019345 @default.
• W2099822807 hasConcept C2778695046 @default.
• W2099822807 hasConcept C2989005 @default.
• W2099822807 hasConcept C71924100 @default.
• W2099822807 hasConceptScore W2099822807C126322002 @default.
• W2099822807 hasConceptScore W2099822807C2777288759 @default.
• W2099822807 hasConceptScore W2099822807C2778019345 @default.
• W2099822807 hasConceptScore W2099822807C2778695046 @default.
• W2099822807 hasConceptScore W2099822807C2989005 @default.
• W2099822807 hasConceptScore W2099822807C71924100 @default.
• W2099822807 hasIssue "1" @default.
• W2099822807 hasLocation W20998228071 @default.
• W2099822807 hasLocation W20998228072 @default.
• W2099822807 hasLocation W20998228073 @default.
• W2099822807 hasLocation W20998228074 @default.
• W2099822807 hasOpenAccess W2099822807 @default.
• W2099822807 hasPrimaryLocation W20998228071 @default.
• W2099822807 hasRelatedWork W2064787237 @default.
• W2099822807 hasRelatedWork W2574683299 @default.
• W2099822807 hasRelatedWork W2807764751 @default.
• W2099822807 hasRelatedWork W2889824157 @default.
• W2099822807 hasRelatedWork W2947337648 @default.
• W2099822807 hasRelatedWork W2969638445 @default.
• W2099822807 hasRelatedWork W3011688938 @default.
• W2099822807 hasRelatedWork W3153293796 @default.
• W2099822807 hasRelatedWork W3164436955 @default.
• W2099822807 hasRelatedWork W4285029842 @default.
• W2099822807 hasVolume "18" @default.
• W2099822807 isParatext "false" @default.
• W2099822807 isRetracted "false" @default.
• W2099822807 magId "2099822807" @default.
• W2099822807 workType "article" @default.